Delivery Order SPE2DR25D2007-SPE2DR26FM12F
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Tavalisse 100 mg tablets (60-count units) with a ceiling value of $18,533.40. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 10, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, indicating it was competed among all eligible...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Tavalisse 100 mg tablets in quantities of 60 units. This is a firm fixed-price delivery order with a ceiling value of $18,533.40 and an ultimate completion date of August 12, 2025. The award represents a non-competitive, non-set-aside delivery order issued under AmerisourceBergen's existing contract vehicle with DLA. Tavalisse is a pharmaceutical product used in the...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Tavalisse 150 mg tablets (60-count) with a contract ceiling value of $18,593.94. This competitively awarded, non-set-aside delivery order utilizes firm fixed price pricing and is scheduled for completion by October 3, 2025. The order will be fulfilled from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Tavalisse 100 mg tablets (60-count units) under a firm fixed-price contract valued at $9,266.70. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of October 16, 2025. AmerisourceBergen will perform this work from its corporate office location in Conshohocken, Pennsylvania, where the company is headquartered. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $9,296.97 to AmerisourceBergen Drug Corp for Tavalisse 150 mg tablets (60-count) on September 3, 2025, with completion expected by September 24, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Tavalisse is a prescription medication used to treat immune thrombocytopenia, a bleeding disorder affecting...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency's Medical Supply Chain on September 5, 2025, for the supply of Tavalisse 100 mg tablets (60-count) with a contract ceiling value of $18,533.40. The contract is structured as a firm fixed price delivery order with an ultimate completion date of September 26, 2025, and carries no set-aside designation, indicating it was competitively awarded. Performance will be executed from the awardee's corporate office...
- The Defense Logistics Agency awarded a $9,266.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 28, 2025, for 60 tablets of Tavalisse 100 mg, a pharmaceutical product for immune thrombocytopenia treatment. The contract, which is a child order under a larger indefinite delivery vehicle, requires completion by November 19, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. This delivery order was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $9,266.70 to AmerisourceBergen Drug Corp for the supply of Tavalisse 100 mg tablets (60-count) under a firm fixed-price contract type. The contract, which was competitively awarded with no set-aside designation, is scheduled for completion by August 25, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Tavalisse 100 mg tablets (60-count units) with a contract ceiling value of $9,266.70. This firm fixed-price delivery order, which is not set-aside and competitively awarded, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a Delivery Order contract valued at $9,797.57 to AmerisourceBergen Drug Corp for the supply of Tavalisse 150 mg tablets (60-count units). This non-competitive, firm fixed-price delivery order was issued on November 5, 2025, with an ultimate completion date of November 28, 2025. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- SPE2DR25D2007Indefinite Delivery Contract
- SPE2DR25D2007-SPE2DR26FM12FDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 13, 2025, for the supply of Tavalisse 100 mg tablets (60-count) with a ceiling value of $9,765.67. This is a firm fixed-price delivery order with an ultimate completion date of December 5, 2025, and carries no set-aside designation, indicating it was awarded through open competition. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. Tavalisse is an immune thrombocytopenia treatment, consistent with the company's portfolio of specialty pharmaceuticals delivered through the DLA's Medical Supply Chain to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.8k | 11/13/25 |